In 2024, major drug approvals in gastroenterology and hepatology included FDA and EMA authorizations of biosimilars to Stelara and Humira for Crohn’s disease and ulcerative colitis, enhancing treatment options for both adult and pediatric patients. Additionally, the FDA approved Hercessi, a biosimilar to Herceptin, for treating HER2-overexpressing metastatic gastric and gastro-esophageal junction adenocarcinoma. These advancements signify strides in expanding therapeutic accessibility and personalized care. Could this trend mark the beginning of a transformative era in GI and hepatology treatments?
Keep Reading
Add A Comment